

SCIENTIFIC CORRESPONDENCE

A case series of Diffuse Glioneuronal Tumours with Oligodendroglioma-like features and Nuclear Clusters (DGONC)

Jessica C Pickles^{1,2}  | Kshitij Mankad³ | Miren Aizpurua⁴ | Simon ML Paine⁵ | Leslie R Bridges⁶ | Fernando Carceller⁷  | Elwira Szycho⁷ | Mark Walker⁸ | Amy R Fairchild^{1,2} | Talisa Mistry² | Olumide Ogunbiyi² | Alice Rolland⁹ | Thomas J Stone^{1,2} | Carryl Dryden¹⁰ | Dilys Addy¹⁰ | Elisa Garimberti¹⁰ | Jane Chalker¹⁰ | Felix Sahn^{11,12,13}  | David TW Jones^{11,14} | Darren Hargrave^{1,15} | Thomas S Jacques^{1,2} 

¹Developmental Biology and Cancer (DBC) Research & Teaching Department, UCL Great Ormond Street Institute of Child Health, London, UK

²Department of Histopathology, Great Ormond Street Hospital for Children, NHS Foundation Trust, London, UK

³Department of Radiology, Great Ormond Street Hospital for Children, NHS Foundation Trust, London, UK

⁴Department of Clinical, Neuropathology King's College Hospital NHS Foundation Trust, London, UK

⁵Queen's Medical Centre Campus, Nottingham University Hospitals NHS Trust, Nottingham, UK

⁶Department of Neuropathology, St George's Hospital NHS Trust, London, UK

⁷Children and Young People's Unit, The Royal Marsden NHS Foundation Trust, Surrey, UK

⁸Cellular Pathology, University Hospital Southampton NHS Foundation Trust, Southampton, UK

⁹Département de Neurochirurgie, Centre Hospitalier Universitaire Montpellier, France

¹⁰Specialist Integrated Haematology and Malignancy Diagnostic Service-Acquired Genomics, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK

¹¹Hopp Children's Cancer Center Heidelberg (KITZ, University Hospital Heidelberg, Heidelberg, Germany)

¹²Department of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany

¹³Clinical Cooperation Unit Neuropathology, German Consortium for Translational Cancer Research (DKTK, German Cancer Research Center (DKFZ, Heidelberg, Germany)

¹⁴Pediatric Glioma Research Group, German Cancer Research Center (DKFZ, Heidelberg, Germany)

¹⁵Department of Paediatric Oncology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK

Correspondence

Thomas S Jacques, UCL GOS Institute for Child Health, 30 Guilford Street, London WC1N 1EH, UK.

Email: t.jacques@ucl.ac.uk

Funding information

Great Ormond Street Hospital Children's Charity; National Institute for Health Research; Brain Tumour Charity; Cancer Research UK; CHILDREN with CANCER UK; Royal Marsden Cancer Charity; Olivia Hodson Cancer Fund

Keywords: brain tumour, paediatric, DNA methylation classification, glioneuronal tumour, monosomy 14We read with interest Deng *et al.*'s recent manuscript concerning a newly molecularly defined glioneuronal CNS tumour entity, termed diffuse glioneuronal tumour with oligodendroglioma-like features and nuclear clusters (DGONC).¹ DGONCs were identified by a distinctive methylation profile that segregated

away from previously recognised molecular groups of CNS tumours. On further review, the authors describe DGONCs as a novel glioneuronal tumour with key neuropathological features including oligodendroglioma-like perinuclear halos and nuclear clusters. At a genetic level, their cohort of 31 DGONCs was found to have recurrent monosomy of chromosome 14 (97%), gain of 1q (26%) and 17q (58%), and

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2020 The Authors. *Neuropathology and Applied Neurobiology* published by John Wiley & Sons Ltd on behalf of British Neuropathological Society.

loss of 19q (35%), but unlike well-characterised glioneuronal tumours, no other defining genetic alterations were identified.

We reviewed our existing paediatric CNS tumour cohorts to determine if we could identify additional cases of DGONC. We reviewed 123 cases with an undetermined final diagnosis originating from two previously described cohorts with existing methylation array data.² From these, we selected tumours that failed to classify using the most up-to-date version of the methylation classifier developed by the DKFZ³ (MNPv11b6) and that had monosomy of chromosome 14.¹ We then performed unsupervised hierarchical clustering using the 10,000 most variably methylated probes for our candidate-DGONC samples together with a cohort of 18 DGONC reported in the original article,¹ along with tumours with a different confirmed molecular diagnosis.^{2,3} Three samples reported were found to have methylation profiles with good similarity to Deng *et al.*'s published cases (Figure 1A, labelled GOSH DGONC) and one patient was later identified as having a second tumour biopsy taken a year later, which also clustered with the reference DGONC cohort.

All patients with a proposed DGONC were male children and, at the time of diagnosis, aged between 11 and 12 years. Case DGONC_1 had been diagnosed as a "malignant glioneuronal tumour", while DGONC_2 and 3 had both been called "high-grade neuroepithelial tumour". These tumours presented as well-defined cortical or subcortical supratentorial masses, and as previously described did not display any specific lobar predisposition. From the available radiology (Figure 1C and Figure S1), the tumours had no appreciable perilesional oedema, were hyperintense compared to cortex on T2 and FLAIR weighting and enhanced poorly with contrast if at all. They also demonstrated internal matrix calcification, with centrally low ADC values on diffusion-weighted images. Imaging for the relapsed case indicated residual tumour but did not show additional radiological features.

All patients are alive and had relatively favourable outcomes, although follow-up time following diagnosis varied between only 0.7 and 6.6 years. Following surgery, all patients received cranio-spinal radiation together with chemotherapy and are in complete


remission. All patients received a gross total resection, the additional surgery for DGONC_1 was to remove persistent residual tumour following chemotherapy and there was no notable progression on radiology (Figure S1). One patient had a previous diagnosis and family history of Autistic Spectrum disorder and Hyperactivity, the other two patients had no known underlying conditions.

Morphologically all three cases had remarkably similar characteristics (see Figure 1D-I and Table S1). They were diffusely arranged tumours composed of round cells with perinuclear haloes, akin to oligodendrogliomas or neurocytic tumours. There were nuclear clusters, at least some of which were part of multinucleate cells. Calcification, ganglion cells, apoptosis and foamy cells were commonly noted. Vascular proliferation was present in two of the four samples. The tumours were of moderate cellularity and the mitotic index ranged between 0.42 and 3.38 per mm², with a focal maximum of 30% of cells staining positive for Ki67. The tumour cells did not express astrocytic markers (e.g. GFAP) but there was diffuse strong staining for neuronal markers Synaptophysin and NeuN, as well as the oligodendrocyte marker OLIG2. CD34 staining was present in the endothelium only. We did not observe histological differences between the primary and secondary DGONC_1 sample.

Apart from the methylation arrays, existing molecular workup did not identify recurrent molecular events (Table S1). Where data were available, no pathogenic variants were observed in the histone H3 genes, and no pathogenic variants or fusion events were detected in *BRAF*. Targeted panel sequencing on DNA and RNA was available for one case (a custom panel⁴ and Illumina TruSight RNA Pan-Cancer fusion Panel, respectively) but failed to reveal any predicted driving molecular events. In addition to monosomy of chromosome 14, on review of the copy number plots, we noted a common focal loss of chromosome 1p (previously not reported) and loss of chromosome 3p.

In conclusion, we have independently identified three DGONCs with consistent histopathological, molecular and clinical features to those previously described. This study confirms that DGONC is a molecularly defined entity with a unique methylation profile

FIGURE 1 Summary of presenting features in three paediatric DGONC. (A) DNA methylation profiling of the new DGONC cases with existing reference cohorts available online via Heidelberg Molecular Neuropathology platform, <https://www.molecularneuropathology.org/mnp>³ and those held locally with a confirmed molecular classification (calibrated score using MNPb11v6 >0.9).² FS and DTWJ kindly provided reference DGONC samples.¹ Samples are coloured according to their methylation class. t-SNE parameters: perplexity = 20, theta = 0.5, dims = 2. (B) Representative copy number plot (DGONC_3) showing previously described features of DGONC: monosomy of chr14, gains in 1p and 17p. Additionally, we noted focal losses in 1p and 3p that were common in our cases series. (C) Radiological features (DGONC_3) of an 11-year-old boy presenting with a mass in the right medial frontal lobe, heterogeneously hyperintense on T2- and FLAIR-weighted sequences with some internal cysts, poorly enhancing with contrast, and rather heterogeneous on diffusion, with a small focus of low ADC values. The CT scan (not shown) revealed calcification in the wall of the cystic area. (D–I) Representative histopathological features observed. Predominant features included rounded nuclei with perinuclear haloes (D–E), clear cell morphology, vascular proliferation and frequent areas of neutrophil (D–G). We observed nuclear aggregation (E, arrows), giant cells and large foamy cells (G). DGONC were negative for glial markers, for example, GFAP (H) and positive for neuronal and oligodendrocyte markers, for example, OLIG2 (I). See extended data for summary table of immunohistochemistry available and additional radiology. Abbreviations (A): CN: central neurocytoma, DGONC: Diffuse Glioneuronal tumour with Oligodendroglia-like features and Nuclear Clusters, DLGNT: diffuse leptomeningeal glioneuronal tumour, DMG K27: diffuse midline glioma with H3 K27M mutation; EFT CIC: Ewings-like family tumour with CIC alteration; GBM RTKI: glioblastoma receptor tyrosine kinase I group; HGNET BCOR: high-grade neuroepithelial tumour with BCOR alteration; HGNET MN1: high-grade neuroepithelial tumour with MN1 alteration; LGG DNT: low-grade glioma, dysembryoplastic neuroepithelial tumour; LGG MYB: low-grade glioma MYB/MYB1; LGG PA/GG ST: low-grade glioma, hemispheric pilocytic astrocytoma and ganglioglioma; NB FOXR2: neuroblastoma with FOXR2 alteration; O IDH: IDH glioma, 1q/19q codeleted oligodendrogloma; DGONC (GOSH): DGONC cases identified at our centre (DGONC_1 to DGONC_3, includes DGONC_1R)



and distinct histopathological features mimicking oligodendroglioma, with the presence of nuclear clusters. All three cases in our small series presented at a similar age (11–12 years) and are all male children, but we assume that this is coincidental as Deng *et al.*'s larger cohort did not observe a gender bias. Monosomy of chromosome 14 is the main recurrent molecular feature of DGONC, and there are no other currently described recurrent pathogenic genetic variants.

ACKNOWLEDGEMENTS

This study was funded by the Brain Tumour Charity, Children with Cancer UK, Great Ormond Street Hospital Children's Charity (INSTINCT), Olivia Hodson Cancer Fund, Cancer Research UK and the National Institute of Health Research. All research at Great Ormond Street Hospital NHS Foundation Trust and UCL Great Ormond Street Institute of Child Health is made possible by the NIHR Great Ormond Street Hospital Biomedical Research Centre.

Archival tissue samples were obtained from the NHS Trusts as part of the UK Brain Archive Information Network (BRAIN UK) which is funded by Brain Tumour Research and the Medical Research Council.

DISCLOSURES

JCP, KM, MA, LRB, FC, ES, MW, ARF, TM, AR, TJS, CD, DA, EG, JC, FS and DH report that they have no conflicts of interest or disclosures. TSJ is the Editor in Chief and SMLP is a member of the editorial board of *Neuropathology and Applied Neurobiology*. The Editors of *Neuropathology and Applied Neurobiology* are committed to peer-review integrity and upholding the highest standards of review. As such, this article was peer reviewed by independent, anonymous expert referees and the authors (including TSJ and SMLP) had no role in either the editorial decision or the handling of the paper. DTWJ has a patent pending: DNA methylation-based method for classifying tumour species of the brain (EP3067432A1).

AUTHOR'S CONTRIBUTIONS

JCP performed the analysis and wrote the manuscript. KM provided and interpreted radiological data, TSJ reviewed the histology. MA, SMLP, LRB, MK, DH and TSJ reported the original diagnostic and clinical findings. CD, DA, EG and JC reported the molecular findings. FC, ES, ARF, TM, OO and AR collected data and TJS provided bioinformatic support. FS and DTWJ provided DGONC reference data. All authors reviewed and accepted the final manuscript.

ETHICAL APPROVAL

This study was covered under ethical approval granted by BRAIN UK tissue bank (REC: 14/SC/0098, references 16/007 and 17/007).

PEER REVIEW

The peer review history for this article is available at <https://publons.com/publon/10.1111/nan.12680>.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request. This article was

peer-reviewed by independent, anonymous expert referees, and the authors (including TSJ and SMLP) had no role in either the editorial decision or the handling of the paper.

ORCID

Jessica C Pickles  <https://orcid.org/0000-0001-7888-1723>

Fernando Carceller  <https://orcid.org/0000-0003-3094-3758>

Felix Sahn  <https://orcid.org/0000-0001-5441-1962>

Thomas S Jacques  <https://orcid.org/0000-0002-7833-2158>

REFERENCES

1. Deng MY, Sill M, Sturm D, et al. Diffuse glioneuronal tumour with oligodendroglioma-like features and nuclear clusters (DGONC) - a molecularly defined glioneuronal CNS tumour class displaying recurrent monosomy 14. *Neuropathol Appl Neurobiol* 2020; 46(5): 422-430
2. Pickles JC, Fairchild AR, Stone TJ, et al. DNA methylation-based profiling for paediatric CNS tumour diagnosis and treatment: a population-based study. *Lancet Child Adolesc Health*. 2020; 4(2): 121-130
3. Capper D, Jones DTW, Sill M, et al. DNA methylation-based classification of central nervous system tumours. *Nature* 2018; 555(7697): 469-474
4. George SL, Izquierdo E, Campbell J, et al. A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations. *Eur J Cancer*. 2019; 121: 224-235

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section.

Fig S1

Table S1

How to cite this article: Pickles JC, Mankad K, Aizpurua M, et al. A case series of Diffuse Glioneuronal Tumours with Oligodendroglioma-like features and Nuclear Clusters (DGONC). *Neuropathol Appl Neurobiol*. 2021;47:464-467. <https://doi.org/10.1111/nan.12680>